RxDoctor Payments Data

Sonya Hance

Family · Newport, TNNPI 1649326596

Payments from drug & device makers

$10,861in general payments, 2019–2025

Across 738 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • GSK$694
  • Amgen$658
  • AstraZeneca$634
  • Lilly USA, LLC$520
  • plus $6K from 49 others

What the payments were for

  • Food & beverage$10,76199%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,861 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$74,851
Medicare patients
196
Services billed
2,309

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept39$288,937
OzempicSemaglutide123$176,513
MounjaroTirzepatide113$160,348
JardianceEmpagliflozin88$115,064
VraylarCariprazine Hcl67$96,014
EliquisApixaban82$86,003
FarxigaDapagliflozin Propanediol79$75,793
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$51,852
OtezlaApremilast11$51,702
CreonLipase/Protease/Amylase28$43,354
KerendiaFinerenone39$40,243
LinzessLinaclotide46$39,227
TrulicityDulaglutide24$37,349
Emgality PenGalcanezumab-Gnlm20$26,847
Nurtec OdtRimegepant Sulfate20$25,543

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Creon, Linzess, Ubrelvy$1,422$199,185155 claims
Novo NordiskOzempic, Rybelsus, Fiasp$1,261$198,809146 claims
Lilly USA, LLCMounjaro, Trulicity$520$197,698137 claims
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$360$143,098114 claims
PfizerEliquis, Nurtec Odt$466$111,546102 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$634$99,110124 claims
GSKTrelegy Ellipta, Anoro Ellipta$694$63,18866 claims
AmgenOtezla$658$51,70211 claims
BayerKerendia$282$40,24339 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$360$24,48514 claims
Esperion Therapeutics, Inc.Nexlizet$177$22,09528 claims
NovartisEntresto$249$21,66422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Newport

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →